What is William Blair’s Forecast for TWST FY2026 Earnings?

Twist Bioscience Co. (NASDAQ:TWST) – Analysts at William Blair issued their FY2026 EPS estimates for shares of Twist Bioscience in a report issued on Monday, November 18th. William Blair analyst M. Larew anticipates that the company will post earnings of ($1.50) per share for the year. The consensus estimate for Twist Bioscience’s current full-year earnings is ($3.13) per share.

Several other research firms have also issued reports on TWST. Robert W. Baird upped their target price on Twist Bioscience from $46.00 to $48.00 and gave the stock an “outperform” rating in a report on Tuesday. JPMorgan Chase & Co. upped their price objective on Twist Bioscience from $28.00 to $35.00 and gave the stock an “underweight” rating in a research note on Monday, August 5th. Scotiabank boosted their target price on shares of Twist Bioscience from $50.00 to $54.00 and gave the stock a “sector outperform” rating in a report on Tuesday. Leerink Partners increased their price target on shares of Twist Bioscience from $45.00 to $48.00 and gave the company a “market perform” rating in a research note on Thursday, October 17th. Finally, Barclays lowered their price objective on shares of Twist Bioscience from $55.00 to $52.00 and set an “overweight” rating on the stock in a research note on Tuesday. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat, Twist Bioscience has an average rating of “Moderate Buy” and a consensus target price of $51.78.

Twist Bioscience Price Performance

Twist Bioscience stock opened at $41.11 on Wednesday. The company has a market cap of $2.41 billion, a price-to-earnings ratio of -10.76 and a beta of 1.78. The firm has a 50-day moving average of $43.93 and a 200-day moving average of $46.15. Twist Bioscience has a one year low of $23.07 and a one year high of $60.90.

Insider Activity

In other Twist Bioscience news, CEO Emily M. Leproust sold 14,334 shares of the business’s stock in a transaction that occurred on Wednesday, November 6th. The shares were sold at an average price of $44.60, for a total transaction of $639,296.40. Following the sale, the chief executive officer now directly owns 589,552 shares of the company’s stock, valued at $26,294,019.20. The trade was a 2.37 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CAO Robert F. Werner sold 1,448 shares of the firm’s stock in a transaction on Wednesday, November 6th. The shares were sold at an average price of $44.60, for a total transaction of $64,580.80. Following the transaction, the chief accounting officer now directly owns 45,620 shares of the company’s stock, valued at $2,034,652. The trade was a 3.08 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 98,118 shares of company stock worth $4,391,151. Corporate insiders own 3.92% of the company’s stock.

Institutional Trading of Twist Bioscience

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Thrivent Financial for Lutherans acquired a new stake in shares of Twist Bioscience in the third quarter valued at about $43,992,000. Point72 Asset Management L.P. increased its position in Twist Bioscience by 1,021.8% during the 2nd quarter. Point72 Asset Management L.P. now owns 673,057 shares of the company’s stock valued at $33,168,000 after purchasing an additional 613,057 shares during the period. Fred Alger Management LLC raised its holdings in Twist Bioscience by 720.7% during the 2nd quarter. Fred Alger Management LLC now owns 654,877 shares of the company’s stock worth $32,272,000 after purchasing an additional 575,080 shares during the last quarter. State Street Corp lifted its position in shares of Twist Bioscience by 19.9% in the 3rd quarter. State Street Corp now owns 3,167,353 shares of the company’s stock worth $143,101,000 after purchasing an additional 526,028 shares during the period. Finally, Wellington Management Group LLP boosted its stake in shares of Twist Bioscience by 188.5% in the 3rd quarter. Wellington Management Group LLP now owns 797,737 shares of the company’s stock valued at $36,042,000 after purchasing an additional 521,272 shares during the last quarter.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.